Abby Hardy, Author at BioTuesdays

Developments

Aptinyx begins Phase 2 study of Parkinson’s disease-associated mild cognitive impairment

Aptinyx (NASDAQ:APTX) launched a Phase 2 study of NYX-458 for the treatment of mild cognitive impairment associated with Parkinson’s disease (PD). NYX-458 is an n-methyl-d-aspartate, or NMDA, receptor modulator. The 135...

December 5, 2019

Developments

Ra Pharma doses first patient in Phase 2 immune-mediated necrotizing myopathy study

Ra Pharmaceuticals (NASDAQ:RARX) dosed the first patient in its Phase 2 clinical trial evaluating zilucoplan for the treatment of immune-mediated necrotizing myopathy (IMNM). IMNM is an autoimmune disease characterized...

December 5, 2019

Developments

Aurinia posts positive Phase 3 voclosporin data in lupus nephritis trial

Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) reported positive efficacy and safety results from its AURORA Phase 3 trial of voclosporin, in combination with mycophenolate (MMF) and low-dose corticosteroids, in the...

December 4, 2019

Developments

Aldeyra reports positive topline results from Phase 3 dry eye disease trial

Aldeyra Therapeutics (NASDAQ:ALDX) reported positive topline results from the first part of its adaptive Phase 3 trial of topical ocular reproxalap for the treatment of dry eye disease. Part 1 of the study assessed...

December 3, 2019

Developments

Hepion’s Drs. Foster, Mayo, Ure and Trepanier appointed adjunct professors at UofA

Hepion Pharmaceuticals’ (NASDAQ:HEPA) Drs. Robert Foster, CEO; Daren Ure, CSO; Daniel Trepanier, SVP drug development; and Patrick Mayo, SVP clinical pharmacology have been appointed adjunct professors by the University...

December 3, 2019

Developments

Kane Biotech selected to receive conditional award of up to $3.4 million for DispersinB development

Kane Biotech (TSX-V:KNE) was selected to receive an award of up to about $3.4-million from an unnamed government agency for the continuing clinical development of DispersinB to treat biofilm mediated antimicrobial...

December 3, 2019

Developments

Evofem Biosciences’ Amphora meets primary and secondary endpoints in Phase 2 trial

Evofem Biosciences (NASDAQ:EVFM) announced positive topline results from its Phase 2b trial evaluating Amphora for the prevention of urogenital chlamydia and gonorrhea in women. The study met its primary and secondary...

December 2, 2019

Developments

Phathom Pharma starts Phase 3 erosive esophagitis trial

Phathom Pharmaceuticals (NASDAQ:PHAT) launched its Phase 3 trial of vonoprazan for the healing and healing maintenance of erosive esophagitis (EE). EE is a type of gastroesophageal reflux disease, or GERD, caused by...

December 2, 2019

Developments

Concert starts Phase 2 study of adjunctive schizophrenia therapeutic candidate

Concert Pharmaceuticals (NASDAQ:CNCE) initiated a Phase 2 study to evaluate its adjunctive schizophrenia therapeutic candidate, CTP-692, in patients who are stable on an antipsychotic medication. CTP-692 is a deuterium...

December 2, 2019

Developments

Akari reports positive data from long-term Phase 2 nomacopan study

Akari Therapeutics (NASDAQ:AKTX) reported new data from an ongoing, long-term Phase 2 study of nomacopan for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). In PNH, the complement system destroys red blood...

December 2, 2019

Author - Abby Hardy

Aptinyx begins Phase 2 study of Parkinson’s disease-associated mild cognitive impairment

Ra Pharma doses first patient in Phase 2 immune-mediated necrotizing myopathy study

Aurinia posts positive Phase 3 voclosporin data in lupus nephritis trial

Aldeyra reports positive topline results from Phase 3 dry eye disease trial

Hepion’s Drs. Foster, Mayo, Ure and Trepanier appointed adjunct professors at UofA

Kane Biotech selected to receive conditional award of up to $3.4 million for DispersinB development

Evofem Biosciences’ Amphora meets primary and secondary endpoints in Phase 2 trial

Phathom Pharma starts Phase 3 erosive esophagitis trial

Concert starts Phase 2 study of adjunctive schizophrenia therapeutic candidate

Akari reports positive data from long-term Phase 2 nomacopan study

Subscribe